Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBT (2020 - 2025)

Oncology Institute (TOI) has disclosed EBT for 6 consecutive years, with -$16.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 2.43% year-over-year to -$16.5 million, compared with a TTM value of -$66.4 million through Sep 2025, up 5.87%, and an annual FY2024 reading of -$64.7 million, up 22.19% over the prior year.
  • EBT was -$16.5 million for Q3 2025 at Oncology Institute, up from -$17.1 million in the prior quarter.
  • Across five years, EBT topped out at $19.5 million in Q1 2022 and bottomed at -$30.0 million in Q1 2023.
  • Average EBT over 5 years is -$11.1 million, with a median of -$15.5 million recorded in 2024.
  • Peak annual rise in EBT hit 3543.21% in 2021, while the deepest fall reached 1625.48% in 2021.
  • Year by year, EBT stood at -$12.6 million in 2021, then grew by 9.9% to -$11.4 million in 2022, then crashed by 67.65% to -$19.1 million in 2023, then skyrocketed by 30.87% to -$13.2 million in 2024, then decreased by 25.2% to -$16.5 million in 2025.
  • Business Quant data shows EBT for TOI at -$16.5 million in Q3 2025, -$17.1 million in Q2 2025, and -$19.6 million in Q1 2025.